Latest Plerixafor Stories
TOORAK, Australia, March 17, 2014 /PRNewswire/ -- Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
Scientists at A*STAR’s Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.
New knowledge of drug mechanism paves road to new treatment approaches for patients suffering from frequent bacterial infectionsSingapore, Nov 14, 2013 - (ACN Newswire)
Stemedica International, SA (Epalinges, Switzerland), a wholly owned subsidiary of Stemedica Cell Technologies, Inc.
New findings by St. Michael's researchers about the way cells work could lead to a test and therapy for kidney failure caused by E. coli.
- A young chicken: also used as a pet name for children.